Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge

References

• DeWitt ME, Polk C, Williamson J, et al. Global mpox case hospitalisation rates: a rapid systematic review and meta-analysis. EClinicalMed. 2022 Dec;54:101710.
   PubMedGoogle Scholar
• Henderson DA. The eradication of smallpox–an overview of the past, present, and future. Vaccine. 2011 Dec 30;29(Suppl 4):D7–D9.
   PubMedGoogle Scholar
• Lum FM, Torres-Ruesta A, Tay MZ, et al. Mpox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol. 2022 Oct;22(10):597–613.
   PubMed Web of Science ®Google Scholar
• Rao AK, Petersen BW, Whitehill F, et al. Use of JYNNEOS (Smallpox and mpox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the advisory committee on immunization practices - United States, 2022. MMWR. 2022 Jun 3;71(22):734–742.
   PubMed Web of Science ®Google Scholar
• Gilchuk I, Gilchuk P, Sapparapu G, et al. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell. 2016 Oct 20;167(3):684–94.e9.
   PubMed Web of Science ®Google Scholar
• Fogg C, Lustig S, Whitbeck JC, et al. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol. 2004 Oct;78(19):10230–7.
   PubMed Web of Science ®Google Scholar
• Fang M, Cheng H, Dai Z, et al. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology. 2006 Feb 5;345(1):231–243.
   PubMed Web of Science ®Google Scholar
• Buchman GW, Cohen ME, Xiao Y, et al. A protein-based smallpox vaccine protects non-human primates from a lethal mpox virus challenge. Vaccine. 2010 Sep 14;28(40):6627–6636.
   PubMed Web of Science ®Google Scholar
• Hooper JW, Thompson E, Wilhelmsen C, et al. Smallpox DNA vaccine protects nonhuman primates against lethal mpox. J Virol. 2004 May;78(9):4433–4443.
   PubMed Web of Science ®Google Scholar
• Huang Q, Ji K, Tian S, et al. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat Commun. 2021 Feb 3;12(1):776.
   PubMed Web of Science ®Google Scholar
• Festing MFW. The “completely randomised” and the “randomised block” are the only experimental designs suitable for widespread use in pre-clinical research. Sci Rep. 2020 Oct 16;10(1):17577.
   PubMed Web of Science ®Google Scholar
• Shomer NH, Allen-Worthington KH, Hickman DL, et al. Review of rodent euthanasia methods. JAALAS. 2020 May 1;59(3):242–253.
   Web of Science ®Google Scholar
• Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020 Aug 6;182(3):722–33.e11.
   PubMed Web of Science ®Google Scholar
• Shi R, Zeng J, Xu L, et al. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. EBioMedicine. 2022 Nov;85:104297.
   PubMed Web of Science ®Google Scholar
• Golovkin M, Spitsin S, Andrianov V, et al. Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6864–6869.
   PubMed Web of Science ®Google Scholar
• Tian S, Ji K, Wang M, et al. Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice. Cell Discov. 2021 Oct 7;7(1):91.
   PubMed Web of Science ®Google Scholar
• Su HP, Golden JW, Gittis AG, et al. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology. 2007 Nov 25;368(2):331–341.
   PubMed Web of Science ®Google Scholar
• Kaever T, Meng X, Matho MH, et al. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J Virol. 2014 Oct;88(19):11339–11355.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discovery. 2018 Apr;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discovery. 2021 Nov;20(11):817–838.
   PubMed Web of Science ®Google Scholar
• Barbier AJ, Jiang AY, Zhang P, et al. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022 Jun;40(6):840–854.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Anand P, Stahel VP. Review the safety of COVID-19 mRNA vaccines: a review. Patient Saf Surg. 2021 May 1;15(1):20.
   PubMed Web of Science ®Google Scholar
• Arevalo CP, Bolton MJ, Le Sage V, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022 Nov 25;378(6622):899–904.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wu M, Zhou C, et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines. 2022 Jul 26;7(1):84.
   PubMed Web of Science ®Google Scholar